The Nasal Polyposis market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Nasal Polyposis: An Overview
Nasal polyps are benign lesions arising from the mucosa of the nasal sinuses (commonly at the outflow tract of one or more of the sinuses) or from the mucosa of the nasal cavity. These polyps usually occur in both the right and left nasal passages and obstruct the flow of air. They can make the nose feel stuffy and can decrease the sense of smell. Not all growths in the nose are polyps. There are two primary types of nasal polyps: ethmoidal and antrochoanal.
Otolaryngologists (ear nose and throat specialists) can detect Nasal Polyposis using a nasal endoscope by looking for translucent grapelike masses colored yellow to gray. CT scanning also will tell if the polyps are coming from the nose or from the sinuses. Nasal polyps almost always occur on both sides. If a polyp is seen only on one side, a CT scan should be done to make sure that the growth is not something more serious. The scan also can accurately show the size of the growth. Large polyps that do not respond to medical therapy usually require surgery. With both treatments, recurrences are common, particularly in patients with asthma who are twice as likely to develop recurrence compared with non-asthmatics.
Nasal Polyposis Market Key Facts
-
As per a study conducted by Cook et al. titled, “Antrochoanal Polyposis: A Review of 33 Cases”, generally, antrochoanal polyps (ACPs) are reported to comprise 3% to 6% of all nasal polyps and the ACP is larger and has a dumbbell shape, related to its growth history.
-
According to a study conducted by DeConde et al. titled “Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis”, polyp recurrence is common after endoscopic sinus surgery with control of polyps up to 18 months found in approximately 60% to 70% of patients.
- As per findings from the secondary domain, females are more commonly affected in the case of Nasal Polyposis than males.
Nasal Polyposis market size is anticipated to increase in the coming years owing to the increasing prevalent population and frequent reoccurrence of Nasal Polyposis patients in the 7MM.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Nasal Polyposis market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the Nasal Polyposis market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Nasal Polyposis Epidemiology
The epidemiology section covers insights about the historical and current Nasal Polyposis patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Nasal Polyposis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Nasal Polyposis market or expected to get launched in the market during the study period. The analysis covers Nasal Polyposis market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Nasal Polyposis Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Get the PDF Sample of the Report:- https://www.delveinsight.com/report-store/nasal-polyposis-market
Nasal Polyposis Therapeutics Analysis
The dynamics of the Nasal Polyposis Market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and also expects the launch of emerging therapies. Companies across the globe are thoroughly working toward the development of new treatment therapies for nasal polyps. The emerging therapies are expected to launch in the coming years.
Some of the key companies in the therapeutic market of Nasal Polyposis at a global level include:
-
Novartis
-
GlaxoSmithKline
-
AstraZeneca
-
Idorsia Pharmaceuticals
-
AnapstysBio
And many others
Nasal Polyposis Therapies covered in the report include:
-
Xolair
-
Mepolizumab
-
Fasenra OSTRO
-
ACT-774312
-
Etokimab
And many more.
Get More Detailed Insights into the Emerging Therapies & Key Companies:- https://www.delveinsight.com/report-store/nasal-polyposis-market
Table of Content
1. Key Insights
2. Executive Summary
3. Nasal Polyposis Competitive Intelligence Analysis
4. Nasal Polyposis Market Overview at a Glance
5. Nasal Polyposis Disease Background and Overview
6. Nasal Polyposis Patient Journey
7. Nasal Polyposis Epidemiology and Patient Population
8. Nasal Polyposis Treatment Algorithm, Current Treatment, and Medical Practices
9. Nasal Polyposis Unmet Needs
10. Key Endpoints of Nasal Polyposis Treatment
11. Nasal Polyposis Marketed Products
12. Nasal Polyposis Emerging Therapies
13. Nasal Polyposis Seven Major Market Analysis
14. Attribute Analysis
15. Nasal Polyposis Market Outlook (7 major markets)
16. Nasal Polyposis Access and Reimbursement Overview
17. KOL Views on the Nasal Polyposis Market.
18. Nasal Polyposis Market Drivers
19. Nasal Polyposis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Request Sample Report here:- https://www.delveinsight.com/report-store/nasal-polyposis-market
Other Latest Report By DelveInsight
Epstein Barr virus (EBV) Market
DelveInsight’s “Epstein Barr virus (EBV) Market” report delivers an in-depth understanding of the Epstein Barr virus (EBV), historical and forecasted epidemiology as well as the Epstein Barr virus (EBV) market trends in 7MM. As per DelveInsight, the Epstein Barr virus (EBV) Market is expected to grow in the coming years owing to the active participation of key companies such as Atara Biotherapeutics, AlloVir, Tessa Therapeutics, Viracta Therapeutics, Seagen, RAPT Therapeutics, Merck, Eutilex, Atara Biotherapeutics, Labolife, and Others.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/